Talk:Olaparib
| This is the talk page for discussing improvements to the Olaparib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Olaparib.
|
Question edit
Does it inhibit just PARP1 or other PARP enzymes ? Rod57 (talk) 11:43, 22 October 2009 (UTC)
Exaggerated coverage edit
The Journal of the National Cancer Institute gave olaparib as an example of exaggerated coverage in the news media. Promoting Healthy Skepticism In The News: Helping Journalists Get It Right
Try to keep out some of the more hysterical claims. --Nbauman (talk) 01:56, 23 November 2009 (UTC)
FDA approved yesterday edit
An FDA news release announces:
- FDA approves Lynparza to treat advanced ovarian cancer
- First LDT companion diagnostic test also approved to identify appropriate patients
Hope this is useful. --Hordaland (talk) 02:08, 20 December 2014 (UTC)
How many people have taken this? edit
It would be helpful to get some statistical estimates of how many people have taken this medication. That would help me, as a consumer, evaluate its effectiveness and safety. I think it's a fairly rare medication, but I'm not sure. — Preceding unsigned comment added by Skysong263 (talk • contribs) 15:16, 8 May 2018 (UTC)
Dangling References edit
Reference #6 (to: http://www.emea.europa.eu/pdfs/human/comp/opinion/51078707en.pdf ) referes to non-existent target.